DS
AKBA icon

DRW Securities’s Akebia Therapeutics AKBA Stock Holding History

DRW Securities’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,443
Closed -$15.9K – 948
2026
Q1 		$15.9K Buy
+11,443
New +$15.7K ﹤0.01% 1217
2025
Q4 		– Sell
-67,824
Closed -$185K – 1216
2025
Q3 		$185K Buy
67,824
+57,142
+535% +$190K ﹤0.01% 1101
2025
Q2 		$38.9K Buy
+10,682
New +$29.4K ﹤0.01% 1044
2024
Q2 		– Sell
-21,000
Closed -$38.4K – 517
2024
Q1 		$38.4K Buy
+21,000
New +$33.6K ﹤0.01% 366

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

DRW Securities's AKBA Position: Q2 2026 in Review

DRW Securities sold out of Akebia Therapeutics (AKBA) in Q2 2026, closing a stake of 11,443 shares — an estimated $15.9K sold.

DRW Securities first reported a position in AKBA in Q1 2024 and held it in 4 quarters. The position peaked at $185K in Q3 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • DRW Securities reported no remaining Akebia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • DRW Securities sold 11,443 Akebia Therapeutics shares in Q2 2026, an estimated $15.9K.
  • DRW Securities first reported a position in Akebia Therapeutics in Q1 2024 and held it in 4 quarters.
  • DRW Securities's Akebia Therapeutics position peaked at $185K in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.